– 31.07.2024: New brand – Spiden is becoming Liom (LinkedIn):
We are thrilled to announce that Spiden is now becoming Liom – pursuing non-invasive glucose monitoring, seamlessly integrated with health metrics into the ultimate wearable
– 05.01.2024: New breakthrough in non-invasive glucose monitoring (Newswire):
Liom Announces Breakthrough in Non-Invasive Glucose Monitoring, Adds Key Executive Hires and Secures $15m in Additional Funding
– 04.09.2023: Disrupting the smart wearables industry (Impulse podcast):
Interview with our CEO Leo Grünstein on how Liom got on the path of creating the most advanced wearable capable of continuously and non-invasively measuring multiple biomarkers circulating in our bodies
– 18.08.2023: Liom will Apple bei Blutzucker-Technik überholen (Handelsblatt):
Das Schweizer Start-up entwickelt einen Handgelenk-Tracker, der den Blutzuckerspiegel ohne Nadelstich misst. Das könnte die Behandlung von Diabetikern einfacher und günstiger machen
– 29.04.2021: Liom raises CHF 18m (Businesswire):
Swiss-based Longevity-focused Startup Liom Raises $18 Million to Expand Its Light+AI-based Real-time Blood Diagnostics Platform
– 15.06.2023: ISO 13485:2016 certification:
Liom has been assessed and certified as meeting the requirements of ISO 13485:2016 for the design and development of non-invasive medical devices for measuring biomarkers and drugs in bodily fluids and tissues
– 11.06.2022: Move into new 1800m2 office & visitor day:
To accomodate our growing team and needs for high-performance infrastructure, Liom has relocated to a new 1800m2 office in Pfäffikon SZ. Marking this significant milestone, we invited partners, investors and other stakeholders to our new facilities